Article

PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophages

2022-01-28

Abstract excerpt

<h4>Background</h4> The immune suppressive tumor microenvironment (TME) that inhibits T cell infiltration, survival, and anti-tumor activity has posed a major challenge for developing effective immunotherapies for solid tumors. Chimeric antigen receptor (CAR)-engineered T cell therapy has shown unprecedented clinical response in treating patients with hematological malignancies, and intense investigation is under...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e4694d58-cd05-59a6-9480-c8972537e815
DOI: 10.1101/2022.01.25.477150

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophagesDOI 10.1101/2022.01.25.477150Read

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity Read

Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype.Semantic proximity Read

Organoid modeling of tumor-associated macrophages reveals phagocytosis checkpoint blockade-induced conversion to an immunosuppressive SPP1+ phenotypeSemantic proximity Read

Breaking the immunosuppressive barrier: an armored CAR-M biotechnology with the original M1 phenotype dominance rescues antitumor immunity.Semantic proximity Read

Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment.Semantic proximity Read

Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy.Semantic proximity Read

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responsesSemantic proximity Read

Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.Semantic proximity Read

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.Semantic proximity Read

Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 ImmunotherapySemantic proximity Read

Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune SurveillanceSemantic proximity Read

Tumor-associated macrophages: functional diversity, clinical significance, and open questions.Semantic proximity Read